{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:55:59Z","timestamp":1774014959910,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Aldosterone-producing adenomas (APAs) vary in phenotype and genotype. Zona glomerulosa (ZG)-like APAs frequently have mutations of an L-type calcium channel (LTCC) Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.3. Using a novel antagonist of Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.3, compound\n                    <jats:bold>8<\/jats:bold>\n                    , we investigated the role of Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.3 on steroidogenesis in the human adrenocortical cell line, H295R and in primary human adrenal cells. This investigational drug was compared with the common antihypertensive drug nifedipine, which has 4.5-fold selectivity for the vascular LTCC, Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.2, over Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.3. In H295R cells transfected with wild-type or mutant Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.3 channels, the latter produced more aldosterone than wild-type, which was ameliorated by 100\u2009\u03bcM of compound\n                    <jats:bold>8<\/jats:bold>\n                    . In primary adrenal and non-transfected H295R cells, compound\n                    <jats:bold>8<\/jats:bold>\n                    decreased aldosterone production similar to high concentration of nifedipine (100\u2009\u03bcM). Selective Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.3 blockade may offer a novel way of treating primary hyperaldosteronism, which avoids the vascular side effects of Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.2-blockade and provides targeted treatment for ZG-like APAs with mutations of Ca\n                    <jats:sub>V<\/jats:sub>\n                    1.3.\n                  <\/jats:p>","DOI":"10.1038\/srep24697","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T05:03:19Z","timestamp":1461214999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Regulation of aldosterone secretion by Cav1.3"],"prefix":"10.1038","volume":"6","author":[{"given":"Catherine B.","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalarukh","family":"Haris Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumedha","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gizem","family":"Tanriver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada E. D.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela","family":"Maniero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soosung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard B.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena A. B.","family":"Azizan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morris J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"key":"BFsrep24697_CR1","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"Funder, J. W. et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93, 3266\u20133281, doi: 10.1210\/jc.2008-0104 (2008).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep24697_CR2","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi, G. P. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48, 2293\u20132300, doi: 10.1016\/j.jacc.2006.07.059 (2006).","journal-title":"J Am Coll Cardiol"},{"key":"BFsrep24697_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrendo.2011.76","volume":"7","author":"GP Rossi","year":"2011","unstructured":"Rossi, G. P. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 7, 485\u2013495, doi: 10.1038\/nrendo.2011.76 (2011).","journal-title":"Nat Rev Endocrinol"},{"key":"BFsrep24697_CR4","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1210\/en.2003-0279","volume":"144","author":"WF Young Jr.","year":"2003","unstructured":"Young, W. F., Jr. Minireview: primary aldosteronism\u2013changing concepts in diagnosis and treatment. Endocrinology 144, 2208\u20132213, doi: 10.1210\/en.2003-0279 (2003).","journal-title":"Endocrinology"},{"key":"BFsrep24697_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1530\/EJE-11-1013","volume":"167","author":"A Hannemann","year":"2012","unstructured":"Hannemann, A. et al. Screening for primary aldosteronism in hypertensive subjects: results from two German epidemiological studies. Eur J Endocrinol 167, 7\u201315, doi: 10.1530\/EJE-11-1013 (2012).","journal-title":"Eur J Endocrinol"},{"key":"BFsrep24697_CR6","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng.2716","volume":"45","author":"EA Azizan","year":"2013","unstructured":"Azizan, E. A. et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 45, 1055\u20131060, doi: 10.1038\/ng.2716 (2013).","journal-title":"Nat Genet"},{"key":"BFsrep24697_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/ng.2695","volume":"45","author":"UI Scholl","year":"2013","unstructured":"Scholl, U. I. et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 45, 1050\u20131054, doi: 10.1038\/ng.2695 (2013).","journal-title":"Nat Genet"},{"key":"BFsrep24697_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/HYPERTENSIONAHA.114.03419","volume":"64","author":"FL Fernandes-Rosa","year":"2014","unstructured":"Fernandes-Rosa, F. L. et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 64, 354\u2013361, doi: 10.1161\/HYPERTENSIONAHA.114.03419 (2014).","journal-title":"Hypertension"},{"key":"BFsrep24697_CR9","unstructured":"Pinggera, A. et al. Human CaV1.3 (CACNA1D) calcium channel mutations associated with hyperaldosteronism or autism risk. Program No. 2012.12 2014 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience. 16th Nov 2014. Available at: http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=5fc23105-4242-4a6b-b284-f1838cc2427e&cKey=4b73446b-97ac-4a41-bd40-78f28c79bbe3&mKey=%7b54C85D94-6D69-4B09-AFAA-502C0E680CA7%7d (Accessed: 7th March 2016)."},{"key":"BFsrep24697_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/CIRCULATIONAHA.107.690396","volume":"116","author":"SJ Hood","year":"2007","unstructured":"Hood, S. J., Taylor, K. P., Ashby, M. J. & Brown, M. J. The spironolactone, amiloride, losartan and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio. Circulation 116, 268\u2013275, doi: 10.1161\/CIRCULATIONAHA.107.690396 (2007).","journal-title":"Circulation"},{"key":"BFsrep24697_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/ncomms2149","volume":"3","author":"S Kang","year":"2012","unstructured":"Kang, S. et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson\u2019s disease. Nat Commun 3, 1146, doi: 10.1038\/ncomms2149 (2012).","journal-title":"Nat Commun"},{"key":"BFsrep24697_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1089\/adt.2013.552","volume":"12","author":"YA Kuryshev","year":"2014","unstructured":"Kuryshev, Y. A., Brown, A. M., Duzic, E. & Kirsch, G. E. Evaluating state dependence and subtype selectivity of calcium channel modulators in automated electrophysiology assays. Assay Drug Dev Technol 12, 110\u2013119, doi: 10.1089\/adt.2013.552 (2014).","journal-title":"Assay Drug Dev Technol"},{"key":"BFsrep24697_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.vascn.2009.02.002","volume":"59","author":"B Balasubramanian","year":"2009","unstructured":"Balasubramanian, B. et al. Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform. J Pharmacol Toxicol Methods 59, 62\u201372 (2009).","journal-title":"J Pharmacol Toxicol Methods"},{"key":"BFsrep24697_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1124\/mol.108.049981","volume":"75","author":"MJ Sinnegger-Brauns","year":"2009","unstructured":"Sinnegger-Brauns, M. J. et al. Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol 75, 407\u2013414, doi: 10.1124\/mol.108.049981 (2009).","journal-title":"Mol Pharmacol"},{"key":"BFsrep24697_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.mce.2015.04.022","volume":"411","author":"S Monticone","year":"2015","unstructured":"Monticone, S. et al. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol 411, 146\u2013154, doi: 10.1016\/j.mce.2015.04.022 (2015).","journal-title":"Mol Cell Endocrinol"},{"key":"BFsrep24697_CR16","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1038\/ncomms4897","volume":"5","author":"NJ Ortner","year":"2014","unstructured":"Ortner, N. J. et al. Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca2+channel activators. Nat Commun 5, 3897, doi: 10.1038\/ncomms4897 (2014).","journal-title":"Nat Commun"},{"key":"BFsrep24697_CR17","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1038\/ncomms5481","volume":"5","author":"H Huang","year":"2014","unstructured":"Huang, H. et al. Modest CaV1.342-selective inhibition by compound 8 is beta-subunit dependent. Nat Commun 5, 4481, doi: 10.1038\/ncomms5481 (2014).","journal-title":"Nat Commun"},{"key":"BFsrep24697_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3949\/ccjm.59.6.617","volume":"59","author":"DJ Triggle","year":"1992","unstructured":"Triggle, D. J. Calcium-channel antagonists: mechanisms of action, vascular selectivities and clinical relevance. Cleve Clin J Med 59, 617\u2013627 (1992).","journal-title":"Cleve Clin J Med"},{"key":"BFsrep24697_CR19","doi-asserted-by":"crossref","unstructured":"Zhou, J. et al. DACH1, a Zona Glomerulosa Selective Gene in the Human Adrenal, Activates Transforming Growth Factor-\u03b2 Signaling and Suppresses Aldosterone Secretion. Hypertension, doi: 10.1161\/hyp.0000000000000025 (2015).","DOI":"10.1161\/HYP.0000000000000025"},{"key":"BFsrep24697_CR20","doi-asserted-by":"crossref","unstructured":"Shaikh, L. H. et al. LGR5 activates non-canonical Wnt-signaling and inhibits aldosterone production in the human adrenal. J Clin Endocrinol Metab, jc20151734, doi: 10.1210\/jc.2015-1734 (2015).","DOI":"10.1210\/jc.2015-1734"},{"key":"BFsrep24697_CR21","first-page":"5488","volume":"50","author":"AF Gazdar","year":"1990","unstructured":"Gazdar, A. F. et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 50, 5488\u20135496 (1990).","journal-title":"Cancer Res"},{"key":"BFsrep24697_CR22","first-page":"E645","volume":"247","author":"K Kojima","year":"1984","unstructured":"Kojima, K., Kojima, I. & Rasmussen, H. Dihydropyridine calcium agonist and antagonist effects on aldosterone secretion. Am J Physiol 247, E645\u2013650 (1984).","journal-title":"Am J Physiol"},{"key":"BFsrep24697_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/00000658-198106000-00007","volume":"193","author":"RE Clark","year":"1981","unstructured":"Clark, R. E. et al. Laboratory and initial clinical studies of nifedipine, a calcium antagonist for improved myocardial preservation. Ann Surg 193, 719\u2013732 (1981).","journal-title":"Ann Surg"},{"key":"BFsrep24697_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(98)07614-4","volume":"353","author":"JE Dickerson","year":"1999","unstructured":"Dickerson, J. E., Hingorani, A. D., Ashby, M. J., Palmer, C. R. & Brown, M. J. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 353, 2008\u20132013 (1999).","journal-title":"Lancet"},{"key":"BFsrep24697_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","volume":"356","author":"MJ Brown","year":"2000","unstructured":"Brown, M. J. et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356, 366\u2013372, doi: 10.1016\/S0140-6736(00)02527-7 (2000).","journal-title":"Lancet"},{"key":"BFsrep24697_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/pgmj.75.882.235","volume":"75","author":"MJ Brown","year":"1999","unstructured":"Brown, M. J. & Hopper, R. V. Calcium-channel blockade can mask the diagnosis of Conn\u2019s syndrome. Postgrad Med J 75, 235\u2013236 (1999).","journal-title":"Postgrad Med J"},{"key":"BFsrep24697_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","volume":"377","author":"MJ Brown","year":"2011","unstructured":"Brown, M. J., McInnes, G. T., Papst, C. C., Zhang, J. & MacDonald, T. M. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 377, 312\u2013320, doi: 10.1016\/S0140-6736(10)62003-X (2011).","journal-title":"Lancet"},{"key":"BFsrep24697_CR28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0022-3565(24)37868-1","volume":"287","author":"MF Rossier","year":"1998","unstructured":"Rossier, M. F., Ertel, E. A., Vallotton, M. B. & Capponi, A. M. Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J Pharmacol Exp Ther 287, 824\u2013831 (1998).","journal-title":"J Pharmacol Exp Ther"},{"key":"BFsrep24697_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1388-9842(01)00159-3","volume":"3","author":"S Glaser","year":"2001","unstructured":"Glaser, S., Steinbach, M., Opitz, C., Wruck, U. & Kleber, F. X. Torsades de pointes caused by Mibefradil. Eur J Heart Fail 3, 627\u2013630 (2001).","journal-title":"Eur J Heart Fail"},{"key":"BFsrep24697_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jsbmb.2004.04.012","volume":"92","author":"VN Uebele","year":"2004","unstructured":"Uebele, V. N., Nuss, C. E., Renger, J. J. & Connolly, T. M. Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells. J Steroid Biochem Mol Biol 92, 209\u2013218, doi: 10.1016\/j.jsbmb.2004.04.012 (2004).","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFsrep24697_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0303-7207(01)00384-7","volume":"175","author":"DP Lotshaw","year":"2001","unstructured":"Lotshaw, D. P. Role of membrane depolarization and T-type Ca2+channels in angiotensin II and K+stimulated aldosterone secretion. Mol Cell Endocrinol 175, 157\u2013171 (2001).","journal-title":"Mol Cell Endocrinol"},{"key":"BFsrep24697_CR32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1210\/endo.132.3.8382595","volume":"132","author":"MF Rossier","year":"1993","unstructured":"Rossier, M. F. et al. Blocking T-type calcium channels with tetrandrine inhibits steroidogenesis in bovine adrenal glomerulosa cells. Endocrinology 132, 1035\u20131043, doi: 10.1210\/endo.132.3.8382595 (1993).","journal-title":"Endocrinology"},{"key":"BFsrep24697_CR33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar, L. et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56, 831\u2013838, doi: 10.1161\/HYPERTENSIONAHA.110.157271 (2010).","journal-title":"Hypertension"},{"key":"BFsrep24697_CR34","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.tips.2011.02.012","volume":"32","author":"A Zuccotti","year":"2011","unstructured":"Zuccotti, A. et al. Structural and functional differences between L-type calcium channels: crucial issues for future selective targeting. Trends Pharmacol Sci 32, 366\u2013375, doi: 10.1016\/j.tips.2011.02.012 (2011).","journal-title":"Trends Pharmacol Sci"},{"key":"BFsrep24697_CR35","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","volume":"29","author":"HK Parthasarathy","year":"2011","unstructured":"Parthasarathy, H. K. et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 29, 980\u2013990, doi: 10.1097\/HJH.0b013e3283455ca5 (2011).","journal-title":"J Hypertens"},{"key":"BFsrep24697_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1365-2265.1977.tb01307.x","volume":"7","author":"D Kremer","year":"1977","unstructured":"Kremer, D. et al. Amiloride in the treatment of primary hyperaldosteronism and essential hypertension. Clin Endocrinol (Oxf) 7, 151\u2013157 (1977).","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BFsrep24697_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.1965.03090020077026","volume":"193","author":"E Clark","year":"1965","unstructured":"Clark, E. Spironolactone Therapy and Gynecomastia. JAMA 193, 163\u2013164 (1965).","journal-title":"JAMA"},{"key":"BFsrep24697_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/S0140-6736(63)91192-9","volume":"1","author":"RM Sussman","year":"1963","unstructured":"Sussman, R. M. Spironolactone and gynaecomastia. Lancet 1, 58 (1963).","journal-title":"Lancet"},{"key":"BFsrep24697_CR39","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1210\/jcem.83.10.5203","volume":"83","author":"M Wehling","year":"1998","unstructured":"Wehling, M. et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 83, 3517\u20133522, doi: 10.1210\/jcem.83.10.5203 (1998).","journal-title":"J Clin Endocrinol Metab"},{"key":"BFsrep24697_CR40","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1210\/en.2006-0826","volume":"147","author":"JW Funder","year":"2006","unstructured":"Funder, J. W. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 147, 5564\u20135567, doi: 10.1210\/en.2006-0826 (2006).","journal-title":"Endocrinology"},{"key":"BFsrep24697_CR41","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1210\/en.2004-1102","volume":"146","author":"G Lee","year":"2005","unstructured":"Lee, G. et al. Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. Endocrinology 146, 2650\u20132656, doi: 10.1210\/en.2004-1102 (2005).","journal-title":"Endocrinology"},{"key":"BFsrep24697_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mce.2013.11.022","volume":"383","author":"CE Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez, C. E. et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol 383, 111\u2013117, doi: 10.1016\/j.mce.2013.11.022 (2014).","journal-title":"Mol Cell Endocrinol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep24697","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24697.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep24697.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:53:36Z","timestamp":1748883216000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep24697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,6]]}},"alternative-id":["BFsrep24697"],"URL":"https:\/\/doi.org\/10.1038\/srep24697","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726303903.793519436","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,21]]},"assertion":[{"value":"10 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24697"}}